Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
November 05 2009 - 5:34PM
PR Newswire (US)
POINT RICHMOND, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Transcept
Pharmaceuticals, Inc. (NASDAQ:TSPT), a specialty pharmaceutical
company focused on the development and commercialization of
proprietary products that address important therapeutic needs in
the field of neuroscience, today announced it will host a webcast
and teleconference with management to discuss third quarter 2009
financial results on Thursday, November 12, 2009, at 5:00 p.m.
Eastern Standard Time. Financial results for the third quarter
ended September 30, 2009 will be released earlier that afternoon.
Conference Call Information Date: Thursday, November 12, 2009 Time:
5:00 p.m. EST Dial-in (U.S.): 877-874-1589 Dial-in (International):
719-325-4805 A simultaneous webcast of the conference call will be
available on the Investors section of the Transcept website at
http://www.transcept.com/. A replay of this webcast will be
available on the website beginning shortly after the conclusion of
the call through November 27, 2009. A telephone replay of the
conference call will be available beginning shortly after the
conclusion of the call through November 27, 2009. The replay
telephone number is 888-203-1112 (U.S.) or 719-457-0820
(International), Replay Passcode: 2918743. About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
proprietary products that address important therapeutic needs in
neuroscience. The most advanced Transcept product candidate is
Intermezzo® (zolpidem tartrate sublingual tablet), for which a New
Drug Application (NDA) was submitted to the U.S. Food and Drug
Administration (FDA) in September 2008 seeking approval as a
prescription sleep aid for use in the middle of the night at the
time a patient awakens and has difficulty returning to sleep. In
October 2009, Transcept received a Complete Response Letter from
the FDA on the Intermezzo® NDA and is working to respond to issues
raised in the letter. Transcept and Purdue Pharmaceutical Products,
L.P. have entered into a collaboration agreement for the
development and commercialization of Intermezzo® in the United
States. For further information, please visit the company's website
at: http://www.transcept.com/. Contacts: Transcept Pharmaceuticals,
Inc. Greg Mann Director of Corporate Communications (510) 215-3567
DATASOURCE: Transcept Pharmaceuticals, Inc. CONTACT: Greg Mann,
Director of Corporate Communications of Transcept Pharmaceuticals,
Inc., +1-510-215-3567, Web Site: http://www.transcept.com/
Copyright